Business
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies for its more
About this update from Phathom Pharmaceuticals, Inc.
[{"type":"text","content":"CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies for its more than 26 million commercially insured members Over 116 million commercially covered lives are now estimated to have access to VOQUEZNA, the first major innovation in Gastroesophageal Reflux Disease (GERD) treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. FLORHAM PARK, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announces that effective immediately, CVS Caremark has added VOQUEZNA® (vonoprazan) tablets to its commercial formularies. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn. VOQUEZNA is the first and only FDA-approved potassium-competitive acid blocker (PCAB) available in the United States. Over 116 million commercially covered lives are now estimated to have access to VOQUEZNA. “We are extremely pleased to have secured widespread commercial coverage for VOQUEZNA while still in the early stages of our product launch,” said Martin Gilligan, Chief Commercial Officer of Phathom. “Today's positive news with the nation’s largest PBM is a significant development for millions of GERD patients seeking an effective new treatment option. Since our last report, an estimated 77% of total commercial lives now have access to our first-in-class GERD treatment. The inclusion of VOQUEZNA on CVS Caremark’s national commercial formularies, requiring only a single step through a generic prescription proton pump inhibitor (PPI), directly aligns with our market access strategy. This achievement underscores our commitment to enhancing patient access and advancing treatment options for those living with acid-related disorders.” Phathom is offering savings programs for eligible patients who face coverage or affordability issues, including a savings card program that allows eligible patients with commercial insurance to pay as little as $25 for their VOQUEZNA prescription. The company has also partnered with BlinkRx, an end-to-e...